In this webinar, we will discuss how to use genetically engineered mouse models (GEMMs) to move your development program from discovery stage to the clinic, including how to use:
Conditional knockout mice to screen candidates in discovery
Humanized immune checkpoint models for proof of concept and initial in vivo screening
CDX and PDX engraftment in immunocompromised mice to generate efficacy and safety data
Dr. Moore and Dr. Suryani Chen will also share data from recent studies validating the use of various models.
Dr. Mark Moore CEO GemPharmatech
Mark is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, he was a co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company, and later served as the Executive Director of the International Mouse Phenotyping Consortium (IMPC). He received his Ph.D. in Biology from Brandeis University studying antibody gene recombination using transgenic mice.
Dr. Santi Suryani Chen Associate Director, Business Development GemPharmatech
Santi is a research scientist with over 10 years of experience in autoimmune disease, immunology, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia, focusing on pediatric leukemia and therapies. Her projects include testing agents' efficacy and mechanisms such as navitoclax, venetoclax, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology.
Date: Thursday, February 17, 2022 Time: 11am ET / 8am PT Duration: 1 Hour